ImStem Biotechnology plans to initiate a phase 1 study of the human embryonic-mesenchymal stem cell agent sometime in 2020. Preclinical data suggest its potential to reduce MS relapses and disability progression, and encourage disease arrest.
Strategies used to monitor patients for treatment response and/or disease progression, and factors that impact clinicians’ decisions to switch to a different therapy for relapsing disease.

SAP Partner Banner